The Weekly Summary

March 13th – March 19th                                 2017

In general news, the national news hyped a Blizzard for the Northeast that never materialized. Continue reading

Posted in - The Weekly Summary | Leave a comment

Insurance companies are not paying for Repatha and Praluent

March 8, 2017- Interviewed by Steven E. Greer, MD

We interviewed cardiologist William O’Neill, MD about his personal need for the cholesterol-lowering, large-molecule, antibody drug from Amgen, branded as Repatha. Despite Continue reading

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | 1 Comment

An emerging safety problem for TAVR patients

March 16, 2017- produced and interviewed by Steven E. Greer, MD

We interviewed William O’Neill, MD, one of the first to implant a Transcatheter Aortic Valve Replacement (TAVR) valve. The products have been approved by the FDA for several years, and we asked him to update us on the real-world usage and safety. Continue reading

Posted in - Medical Devices, Cardiac surgery, Cardiology, FDA | Leave a comment

The Lotus TAVR valve recall

March 16, 2017- produced and interviewed by Steven E. Greer, MD

We interviewed William O’Neill, MD, one of the first to implant a Transcatheter Aortic Valve Replacement Continue reading

Posted in - Medical Devices, Cardiac surgery, Cardiology, FDA | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

The Healthcare Channel hits 10

 February 3, 2017- by Steven E. Greer, MD

I don’t recall the exact date, but it was sometime during the summer of 2006, when I was daydreaming Continue reading

Posted in - Opinion | 1 Comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD

We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber, Continue reading

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Current surgical weight loss therapies

January 24, 2014- Interviewed by Steven E. Greer, MD

Erik Dutson, MD, weight loss surgeon at UCLA, explains why his medical center does not implant the Lap-Band, Continue reading

Posted in - Medical Devices, Bariatric surgery, General surgery, UCLA | Leave a comment

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD Continue reading

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | 1 Comment

The Weekly Summary

March 6th – March 12th                                 2017               

In general news, South Korea’s President was impeached. “Towergate” seems to have backfired Continue reading

Posted in - The Weekly Summary | Leave a comment

The Who’s Teen Cancer Lounge at Sloan Kettering opens

March 18, 2016- by Steven E. Greer MD

The Memorial Sloan Kettering Cancer Center held a press day for its new teen lounge Continue reading

Posted in Memorial Sloan-Kettering, Oncology | Leave a comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - Generics, FDA | Leave a comment

Changes in plastic surgery training programs

March 3, 2015- Interviewed by Steven E. Greer, MD

In Part 1 of our interview with the new Chairman of Plastic Surgery at NYU, Eduardo Rodriguez, Continue reading

Posted in - Policy, NYU, Plastic surgery | Leave a comment

Vagal nerve stimulation for weight loss

January 22, 2015- Interviewed by Steven E. Greer, MD

Erik Dutson, MD, bariatric surgeon from UCLA, discusses the newly FDA-approved weight loss device called Continue reading

Posted in - Medical Devices, Bariatric surgery, Diabetes and endocrinology, Gastroenterology and liver, Primary care medicine, UCLA | Leave a comment

How the FDA regulates compounding pharmacies

April 5, 2015- Interviewed by Steven E. Greer, MD

Few people knew what a compounding pharmacy was until a meningitis outbreak traced to the Continue reading

Posted in - Policy, FDA | 1 Comment

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD

Jonathan Strosberg, MD of Continue reading

Posted in - NEJM, Oncology | Leave a comment

Interview with the CEO of Neovasc, Alexei Marko

Posted in - Medical Devices, Cardiology, FDA | Leave a comment

Interview with Dexcom’s CEO Terry Gregg

August 11, 2014- Interviewed by Steven E. Greer, MD

Above, in Continue reading

Posted in - Medical Devices | Leave a comment

Interview with MannKind’s CEO, Al Mann, and CFO, Matt Pfeffer.

October 23, 2013- Interviewed by Steven E. Greer, MD

The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer. Continue reading

Posted in - Medical Devices, Diabetes and endocrinology, FDA | Leave a comment

The Weekly Summary

February 27th – March 5th                                 2017

 In general news, this was President Trump’s week. His State of the Union speech amazed Continue reading

Posted in - The Weekly Summary | Leave a comment